BioTime to Produce Stem Cells for Research in Muscle Disorders

BioTime to Produce Stem Cells for Research in Muscle Disorders

Press Release | January 3, 2012

ALAMEDA, Calif., Jan 03, 2012 (BUSINESS WIRE) — BioTime, Inc. BTX +0.51% today announced that it has elected to market progenitors of muscle stem cells bearing hereditary diseases. BioTime will produce the products from five human embryonic stem (hES) cell lines from Reproductive Genetics Institute (RGI) of Chicago, Illinois. The muscle cell lines will display the genes for Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, spinal muscular atrophy Type I, facioscapulohumeral muscular dystrophy 1A, and Becker muscular dystrophy. The cell lines will be marketed researchers seeking new treatment modalities for these diseases.

“In the first quarter of this year, we will offer medical researchers normal muscle progenitor cell lines that we have already produced from BioTime’s existing hES cell lines, and later in 2012 we plan to add to our product line the novel muscle progenitor cells produced from RGI cell lines bearing the five genetic muscle diseases,” said Michael West, Ph.D., BioTime’s CEO. “BioTime’s business strategy includes generating near-term revenues in the emerging field of regenerative medicine by bringing some of the most advanced stem cell technologies to the market as research products.”

Click HERE or on the image below to read more…


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: